Events2Join

Prognostic Impact of BRAF and KRAS Mutation in Patients with ...


Prognostic Impact of BRAF and KRAS Mutation in Patients ... - PubMed

BRAF mutation is a marker of poor prognosis in patients with appendiceal and colorectal peritoneal metastases scheduled for CRS and HIPEC, whereas survival ...

Prognostic Impact of BRAF and KRAS Mutation in Patients with ...

Conclusions. BRAF mutation is a marker of poor prognosis in patients with appendiceal and colorectal peritoneal metastases scheduled for CRS and ...

Prognostic Effect of BRAF and KRAS Mutations in Patients With ...

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Prognostic impact of BRAF and KRAS mutations according to the ...

Conclusions:BRAFV600E mutations have poor prognostic value specific to MSS tumors in CMS1, while KRAS mutations are associated with adverse outcome in MSS ...

Incidence and prognostic impact of KRAS and BRAF mutation in ...

Molecular biomarkers offer the potential for refining prognostic determinants in patients undergoing cancer surgery. Among patients with ...

CMS-dependent prognostic impact of KRAS and BRAFV600E ...

BRAFV600E and KRAS mutations were both associated with inferior 5-year overall survival (OS) exclusively in MSS tumors (BRAFV600E mutation versus KRAS/BRAF wild ...

Prognostic impact of mutation profiling in patients with stage II and III ...

KRAS, BRAF and NRAS mutations do not have major prognostic value in stage II and III colon cancer, subtypes of gene mutations should be further investigated.

CMS-dependent prognostic impact of KRAS and BRAF V600E ...

BRAFV600E and KRAS mutations were both associated with inferior 5-year overall survival (OS) exclusively in MSS tumors (BRAFV600E mutation versus KRAS/BRAF wild ...

Prognostic effect of RAS/BRAF mutations in patients (pts) with ...

The numerically higher mOS in pts with KRAS G12C and non-codon 12 KRAS mutations merit further biologic characterization with functional assays.

The prognostic significance of KRAS and BRAF mutation status in ...

BRAF mutation, rather than KRAS, was a significant prognostic factor in Korean CRC patients at both early and advanced stages.

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in ...

Activation of oncogenes downstream the EGFR gene contributes to colorectal tumorigenesis and determines the sensitivity to anti-EGFR ...

KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers ...

Interestingly, patients with KRAS mutations were associated with a poor response to first line standard chemotherapy (p = 0.008). In contrast, the BRAF V600E ...

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as ...

Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors.

Incidence and prognostic impact of KRAS and BRAF mutations in ...

Background: Molecular biomarkers offer the potential for refining prognostic determinants in patients undergoing cancer surgery.

BRAF and KRAS mutations in metastatic colorectal cancer

The BRAF mutation is also a strong indicator of poor prognosis in mCRC; the addition of an anti-EGFR agent had a detrimental effect on survival ...

Prognostic value of KRAS and BRAF mutations in curatively ...

Patient characteristics according to KRAS or BRAF status are summarized in Table 1. MSI status was determined in all cases, whereas mutation status was not ...

Association of BRAF Mutations With Survival and Recurrence in ...

Of importance, our analysis indicated that the BRAF V600E mutation may be not only a stronger prognostic factor than KRAS, thus confirming the ...

(PDF) Prognostic Impact of BRAF and KRAS Mutation in Patients ...

Conclusions: BRAF mutation is a marker of poor prognosis in patients with appendiceal and colorectal peritoneal metastases scheduled for CRS and HIPEC, whereas ...

Specific Mutations in KRAS Codons 12 and 13, and Patient ...

To assess prognostic roles of KRAS mutations in colorectal cancer, BRAF mutation status must be controlled because BRAF-mutated cancers are associated with ...

Original Article Prognostic impact of KRAS and BRAF mutations in ...

Approximately 25% of CRC patients will present with synchronous colorectal liver metastases. (SCRLMs) at the initial diagnosis, and 25~50% of ...